Resource data sheet
Prev.
Please review the QC test results indicated by check icon below as well as clone information before placing your order.

DNMT3B px330

Expression vector of guide RNA for targeting human DNMT3B exon 6.

Catalog number RDB17378
Resource name DNMT3B px330
Alternative name DNMT3B exon6 pX330-U6-Chimeric_BB-CBh-hSpCas9
Clone info. Expression vector of guide RNA for targeting human DNA methyltransferase 3 beta (DNMT3B) exon 6 (5'-GAGACGGCGGGCAACAGCAT-3') and human codon-optimized SpCas9.
Vector backbone pX330-U6-Chimeric_BB-CBh-hSpCas9 (plasmid)
Size of vector backbone 8.5 kb
Selectable markers Amp^r (E. coli)
Gene/insert name human DNMT3B dsOligo
Depositor|Developer Unoki, Motoko |
Other clones in our bank

External Database
human DNMT3B

          Reference sequence
            
           

          Distribution information

          Please check terms and conditions set forth by the depositor, which are specified in the RIKEN BRC Catalog and/or Web Catalog.
          Terms and conditions for distribution In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of literature designated by the DEPOSITOR (Unoki, M et al. J. Clin. Invest. 129 (1), 78-92, 2019) and an acknowledgment to the DEPOSITOR are requested.
          Ordering
          Order form [Credit Card Payment]  [Bank Transfer Payment]
          Exclusive MTA (For the DNA materials containing CRISPR/Cas9 technologies and for not-for-profit academic purpose) [Word]
          Please visit Information of Request for Distribution.[link] 
          Remarks
          The BIOLOGICAL RESOURCE contains CRISPR/Cas9 technologies and is not provided to for-profit organization or for for-profit research by non-profit organizations.
          提供案内 (日本国内) [open/close]

          提供条件 利用者は、研究成果の公表にあたって寄託者の指定する文献 (Unoki, M et al. J. Clin. Invest. 129 (1), 78-92, 2019) を引用し、謝辞の表明を必要とする。
          提供依頼
          提供依頼書 [Word]
          専用MTA(CRISPR/Cas9内包遺伝子材料専用 非営利学術目的)をお使いください [Word]
          手続きの概要は、「提供申込みについて[link]」をご覧ください。
          備考
          本件リソースはCRISPR/Cas9 technologyを用いたゲノム編集バイオリソースです。営利機関および非営利機関による営利目的研究には提供いたしません。

          Catalog # Resource name Shipping form Fee (non-profit org.)
          RDB17378 DNMT3B px330 DNA solution

          Please review the QC test results indicated by check icon below as well as clone information before placing your order.

          How to cite this biological resource

          Materials & Methods section:

          The DNMT3B px330 was provided by the RIKEN BRC through the National BioResource Project of the MEXT, Japan (cat. RDB17378).

          Reference section:

          Unoki, M., Funabiki, H., Velasco, G., Francastel, C., Sasaki, H., CDCA7 and HELLS mutations undermine nonhomologous end joining in centromeric instability syndrome. J. Clin. Invest. 129 (1): 78-92 (2019). PMID 30307408. [link to RRC of NBRP]

          Further references such as user reports and related articles (go to bottom)


          Tips

          Featured content


          QC test results

          RIKEN BRC has sequenced portions of this material for quality test.
          Please review the QC test results indicated by check icon as well as clone information before placing your order.

          Test sheet RDB17378_A9Fhp1-1.pdf check

          Nucleotide sequence of a portion of this resource (if available).

          Primer: SV40pA3'element reverse (Pr0108)
          Region: U6 pro, gRNA (DNMT3B) gRNA scaffold, CBh pro 5'
          Sequence file: RDB17378_A9Fha.seq check
          >D06399A5_A9Fh_2_SV40pA3'element reverse_H01_08_ABI08.ab1
              1 NNNNNNNNNN NNNNNNNNNN NNGGNNNNNN CNNGCAACGC GGCCTTTTTA CGGTTCCTGG
             61 CCTTTTGCTG GCCTTTTGCT CACATGTGAG GGCCTATTTC CCATGATTCC TTCATATTTG
            121 CATATACGAT ACAAGGCTGT TAGAGAGATA ATTGGAATTA ATTTGACTGT AAACACAAAG
            181 ATATTAGTAC AAAATACGTG ACGTAGAAAG TAATAATTTC TTGGGTAGTT TGCAGTTTTA
            241 AAATTATGTT TTAAAATGGA CTATCATATG CTTACCGTAA CTTGAAAGTA TTTCGATTTC
            301 TTGGCTTTAT ATATCTTGTG GAAAGGACGA AACACCGATG CTGTTGCCCG CCGTCTCGTT
            361 TTAGAGCTAG AAATAGCAAG TTAAAATAAG GCTAGTCCGT TATCAACTTG AAAAAGTGGC
            421 ACCGAGTCGG TGCTTTTTTG TTTTAGAGCT AGAAATAGCA AGTTAAAATA AGGCTAGTCC
            481 GTTTTTAGCG CGTGCGCCAA TTCTGCAGAC AAATGGCTCT AGAGGTACCC GTTACATAAC
            541 TTACGGTAAA TGGCCCGCCT GGCTGACCGC CCAACGACCC CCGCCCATTG ACGTCAATAG
            601 TAACGCCAAT AGGGACTTTC CATTGACGTC AATGGGTGGA GTATTTACGG TAAACTGCCC
            661 ACTTGGCAGT ACATCAAGTG TATCATATGC CNAGTACGCC CCCTATTGAC GTCAATGACG
            721 GTAAATGNNC CGCCTGGCAT TGTGCCCAGT ACATGACCTT ATGNNNCTNT CCTACTTGGC
            781 AGTACATCTA CGTATTAGTC ATCNCTATTA CCATGGTCNA NGTGAGCCCC ACGTTCTGCT
            841 TCACTCTCCC NNTCNCCCCC CCCNTCCCNN CCCCCNATTT TGNATTTATT TATTTTTTTA
          901 ATTATTTTGT GCNGCGANGG GNGNNNNNNN NNN
          //
          Primer: Cas9-N_R1 (Pr0650)
          Region: Cas9 5', SV40 NLS, 3xFLAG, CBh pro 3'
          Sequence file: RDB17378_A9Fhb.seq check
          >D06399A5_A9Fh_2_Cas9-N_R1_A02_02_ABI24.ab1
              1 NNNNNNNNNN NNNNNNNNNN NNNTGNNCTC GTCGGTGNNC ACGGCCCNGC CCACAGAGTT
             61 GGTGCCGATG TCCAGGCCGA TGCTGTACTT CTTGTCGGCT GCTGGGACTC CGTGGATACC
            121 GACCTTCCGC TTCTTCTTTG GGGCCATCTT ATCGTCATCG TCTTTGTAAT CAATATCATG
            181 ATCCTTGTAG TCTCCGTCGT GGTCCTTATA GTCCATGGTG GCACCGGTCC AACCTGAAAA
            241 AAAGTGATTT CAGGCAGGTG CTCCAGGTAA TTAAACATTA ATACCCCACC AACCAACCAT
            301 CCCTTAAACC CTTACCTCTT GCTCAGCTAA TTACAGCCCG GAGGAGAAGG GCCGTCCCGC
          361 CCGCTCACCT GTGGGAGTAA CGCGGTCAGT CAGAGCCGGG GCGGGCGGCG CGAGGCN
          //
          Primer: BGH_rev2 (Pr0606)
          Region: bGH p(A), nucleoplasmin NLS, Cas9 3'
          Sequence file: RDB17378_A9Fhc.seq check
          >D06399A5_A9Fh_2_BGH_rev2_G02_20_ABI24.ab1
              1 NNNNNNNNNN NNNNNNNNNN NNNNNNNNNG GGCNNACNAC AGATGGCTGG CAACTAGAAG
             61 GCACAGTCGA GGCTGATCAG CGAGCTCTAG GAATTCTTAC TTTTTCTTTT TTGCCTGGCC
            121 GGCCTTTTTC GTGGCCGCCG GCCTTTTGTC GCCTCCCAGC TGAGACAGGT CGATCCGTGT
            181 CTCGTACAGG CCGGTGATGC TCTGGTGGAT CAGGGTGGCG TCCAGCACCT CTTTGGTGCT
            241 GGTGTACCTC TTCCGGTCGA TGGTGGTGTC AAAGTACTTG AAGGCGGCAG GGGCTCCCAG
            301 ATTGGTCAGG GTAAACAGGT GGATGATATT CTCGGCCTGC TCTCTGATGG GCTTATCCCG
            361 GTGCTTGTTG TAGGCGGACA GCACTTTGTC CAGATTAGCG TCGGCCAGGA TCACTCTCTT
            421 GGAGAACTCG CTGATCTGCT CGATGATCTC GTCCAGGTAG TGCTTGTGCT GTTCCACAAA
            481 CAGCTGTTTC TGCTCATTAT CCTCGGGGGA GCCCTTCAGC TTCTCATAGT GGCTGGCCAG
            541 GTACAGGAAG TTCACATATT TGGAGGGCAG GGCCAGTTCG TTTCCCTTCT GCAGTTCGCC
            601 GGCAGAGGCC AGCATTCTCT TCCGGCCGTT TTCCAGCTCG AACAGGGAGT ACTTAGGCAG
            661 CTTGATGATC AGGTCCTTTT TCACTTCTTT GTAGCCCTTG GCTTCCAGAA AGTCGATGGG
            721 ANTCTTCTCG AAGCTGCTTC TTTCCATGAT GGTGATCCCC AGCAGCTCTT TCACACTCTT
            781 CAGTTTCTTG GANTTGCCCT TTTCCACTTT GGCCACCACC AGCACAGAAT ANGCCACGGN
            841 GGGGCTGTCG AANCCGCCNT ACTTCTTANG GTCCCAGTCC TTCTTTNTGG CGATCAGCTT
            901 ATCNCTGTTN NNCNNGGGNA NGANAGANTC TTTGCTGAAN CCGNCNGNCT GCNNNNNGGN
          961 CTTTTTCNCN ATATTCNNNN GGGGNANGNN CNNNNNNTNN NNNNNNNN
          //

          Please visit Sequencing and PCR primers for primer information.


          References

          Original, user report and related articles

          original Unoki, M., CDCA7 and HELLS mutations undermine nonhomologous end joining in centromeric instability syndrome. J. Clin. Invest. 129 (1): 78-92 (2019). PMID 30307408. [link to RRC of NBRP]

          2023.08.17

          GNP_filter3_RDBDEP_html_230702.pl